Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227298 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
A Phase 1 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 162
- Enrollment target
- 5
- Study locations
NCT07227298 is a Phase 1 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Pfizer. The registered enrollment target is 162 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT07227298, a Phase 1 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 162 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B of the study will look at how well the new medicine PF-08634404 works when used together with another medicine. Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
Conditions Studied
Interventions
- BIOLOGICAL PF-08634404
- BIOLOGICAL Sigvotatug Vedotin
- BIOLOGICAL Combination Agent 1
Study Locations (5)
Other
- Pan American Center for Oncology Trials, LLC - San Juan
- BRCR Global Puerto Rico - Hato Rey - San Juan
Florida
- Mid Florida Hematology and Oncology Center - Orange City
Oregon
- Oncology Associates of Oregon, P.C - Eugene
Osaka
- Kansai Medical University Hospital - Hirakata
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2033-08-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227298
The ClinicalTrials.gov registry entry for NCT07227298 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which PF-08634404 is the first listed.
NCT07227298 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Oregon.
Frequently Asked Questions
What is clinical trial NCT07227298 about?
NCT07227298 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers". This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or...
What is the current status of trial NCT07227298?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2026-01-30. Estimated completion is 2033-08-23.
What conditions does trial NCT07227298 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Advanced/Metastatic Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT07227298?
The interventions under investigation include: PF-08634404 (BIOLOGICAL), Sigvotatug Vedotin (BIOLOGICAL), Combination Agent 1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07227298?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227298 being conducted?
This trial has 5 study locations across Florida, Oregon, Osaka. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.